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List of abbreviations 
ECE-1  endothelin-converting enzyme 1 
ECE-2  endothelin-converting enzyme 2 
EDN1  endothelin-1 
α-syn  alpha-synuclein 
α-syn-P129 alpha-synuclein phosphorylated at serine-129 
Aβ  beta-amyloid 
DLB  dementia with Lewy bodies 
AD  Alzheimer’s disease 
KLK6  kallikrein-6  
CAPN1  calpain-1 
CTSD  cathepsin-D 
M6PR  mannose-6-phosphate receptor 
Rab5  small Rab GTP(guanosine triphosphate)ase-5 
Rab7  small Rab GTP(guanosine triphosphate)ase-7 
EEA1  early endosome autoantigen-1 
NAC  non-amyloid beta component 
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In this issue. Defective clearance, rather than increased production, most likely contributes to intracellular 
accumulation of α-synuclein in Lewy body diseases, including dementia with Lewy bodies (DLB) and 
Parkinson’s disease (PD). Several enzymes are capable of degrading α-synuclein (as shown) and are often 
dysregulated in DLB and PD. Here we show for the first time that recombinant human α-synuclein is cleaved by 
endothelin-converting enzyme-1 and -2 (ECE-1/-2) and siRNA-mediated knockdown of ECE-1 or -2 increased 
intracellular and extracellular α-syn within SH-SY5Y cells. ECE-1 and -2 co-localise with discrete pools of 
intracellular α-synuclein that are implicated in the spread and propagation of Lewy body pathology. Finally, we 
show that ECE-1 and -2 levels are significantly reduced in post-mortem brain tissue in the cingulate cortex in 
DLB and correlate inversely with Lewy body pathology.  
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Abstract We have examined the roles of the endothelin-converting enzyme-1 and -2 (ECE-1 and ECE-2) in the 
homeostasis of α-synuclein (α-syn) and pathogenesis of Lewy body disease. The ECEs are named for their 
ability to convert inactive big endothelin to the vasoactive peptide endothelin-1 (EDN1). We have found that 
ECE-1 and ECE-2 cleave and degrade α-syn in vitro and siRNA-mediated knockdown of ECE-1 and ECE-2 in 
SH-SY5Y neuroblastoma cells significantly increased α-syn both intracellularly (within the cell lysate) (P < 
0.05 for both ECE-1 and -2) and extracellularly (in the surrounding medium) (P < 0.05 for ECE-1 and P = 0.07 
for ECE-2). Double immunofluorescent labelling showed co-localisation of ECE-1 and ECE-2 with α-syn 
within the endolysosomal system (confirmed by a proximity ligation assay). To assess the possible relevance of 
these findings to human Lewy body disease, we measured ECE-1 and ECE-2 levels by sandwich ELISA in post-
mortem samples of cingulate cortex (a region with a predilection for Lewy body pathology) in dementia with 
Lewy bodies (DLB) and age-matched controls. ECE-1 (P < 0.001) and ECE-2 (P < 0.01) levels were 
significantly reduced in DLB and both enzymes correlated inversely with the severity of Lewy body pathology 
as indicated by the level of α-syn phosphorylated at Ser129 (r = -0.54, P < 0.01 for ECE-1 and r = -0.49, P < 
0.05 for ECE-2). Our novel findings suggest a role for ECEs in the metabolism of α-syn that could contribute to 
the development and progression of DLB. 
 
Introduction 
Abnormal aggregates of α-synuclein (α-syn) within neuronal perikarya (as Lewy bodies) and neurites (as Lewy 
neurites) are the defining neuropathological hallmarks of Parkinson’s disease (PD) and dementia with Lewy 
bodies (DLB). Accumulation of insoluble (Campbell et al. 2000) and soluble oligomeric α-syn (Paleologou et 
al. 2009) in sporadic PD and DLB, without an increase in α-syn mRNA (Kingsbury et al. 2004, Wirdefeldt et al. 
2001), suggest a major role for impaired clearance in the pathogenesis of these diseases. Dysregulation of the 
ubiquitin-proteasome system (UPS) and the autophagy-lysosomal pathway (ALP) probably contributes to the 
accumulation of α-syn, particularly in familial Lewy body disease (reviewed in (Deleidi & Maetzler 2012, 
Ebrahimi-Fakhari et al. 2012, Webb et al. 2003, Xilouri et al. 2013)). Cathepsin D (CTSD), the major lysosomal 
protease responsible for α-syn cleavage (Cullen et al. 2009, Qiao et al. 2008, Sevlever et al. 2008), is 
upregulated in PD and DLB (Yelamanchili et al. 2011). A small number of non-lysosomal proteolytic enzymes 
have been identified that cleave α-syn in vitro, including MMP-3, −9 (Sung et al. 2005), calpain-1 (CAPN1) 
(Mishizen-Eberz et al. 2003, Mishizen-Eberz et al. 2005) and kallikrein-6 (KLK6) (Iwata et al. 2003, Kasai et 
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al. 2008). These are expressed within the cytosol, or are released extracellularly, whereupon they are activated 
and are likely to interact with and degrade distinct pools of α-syn that are important in the accumulation and 
transneuronal spread of pathogenic α-syn (Luk et al. 2012, Mougenot et al. 2011, Mougenot et al. 2012, 
Masuda-Suzukake et al. 2013). We reported previously that the levels of CAPN-1 and KLK6 are reduced in the 
cingulate cortex in DLB (Miners et al. 2014a). 
Endothelin-converting enzymes (ECE; EC number 3.4.24.71) are type II membrane metallopeptidases 
named for their ability to convert the inactive precursor big endothelin to endothelin-1, a potent vasoactive 
peptide. ECE-1 and ECE-2 share 59% sequence homology and cleave a similar range of substrates although 
ECE-1 is most active at a neutral pH whereas ECE-2 is most active at a mildly acidic pH (Emoto & Yanagisawa 
1995). ECE-1 is expressed abundantly in endothelial cells in all organs but has also been identified within non-
vascular cells within the CNS such as pyramidal neurons, cerebellar Purkinje cells and astrocytes (Naidoo et al. 
2004, Palmer et al. 2010). Four isoforms of ECE-1 have been identified (ECE-1a, b, c, d): ECE-1a and ECE-1c 
reside within the plasma membrane (Muller et al. 2003, Schweizer et al. 1997) whereas ECE-1b and d are 
located within intracellular compartments including the endolysosomal system (Muller et al. 2003, Azarani et al. 
1998, Schweizer et al. 1997). ECE-1 degrades a variety of neuropeptides (substance P, bradykinin, neurotensin, 
somatostatin etc) intracellularly within endosomes at a mildly acidic pH (Fahnoe et al. 2000, Johnson et al. 
1999, Roosterman et al. 2008, Cottrell et al. 2009, Cattaruzza et al. 2009, Hasdemir et al. 2012). ECE-2 is 
mostly expressed in neural tissue and has been predominantly detected in pyramidal neurons but is also 
expressed in astrocytes and microglia (Palmer et al. 2010). All four ECE-2 variants are located within 
intracellular secretory vesicles and they too are capable of intracellular neuropeptide degradation in mildly 
acidic conditions (Gupta et al. 2015, Pacheco-Quinto & Eckman 2013). The expression and function of ECE-2 
is not yet fully characterised. 
ECEs hydrolyse amyloid-β (Aβ) peptide in vitro (Eckman et al. 2001) and have been implicated in the 
pathogenesis of Alzheimer’s disease (AD). Endogenous Aβ levels were elevated in ECE knockout mice 
(Eckman et al. 2003). A recent study reported that ECEs degrade two distinct pools of intracellular Aβ: ECE-2 
cleaved an intracellular pool within the autophagic and endolysosomal pathway whereas ECE-1 predominantly 
degraded a pool of Aβ destined for secretion (Pacheco-Quinto & Eckman 2013). In the present study, we have 
shown that ECE-1 and ECE-2 degrade α-syn in vitro and have investigated their contributions to the 
pathogenesis of dementia with Lewy bodies (DLB).  
 
Page 5 of 37 Journal of Neurochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
6 
 
Materials and Methods 
Study cohort  
Brain tissue was obtained from the South West Dementia Brain Bank, University of Bristol, with local Research 
Ethics Committee approval (08/H0106/28+5). The brains had been separated midsagittally - the left half sliced 
and frozen at −80°C and the right half fixed in formalin for paraffin histology and detailed neuropathological 
examination. We examined 11 DLB and 15 control brains matched for age, gender and post-mortem (PM) delay 
(Table 1). The DLB group had an average age-at-death of 77.7 ± 8.9 years and a post-mortem delay of 28.2 ± 
10.3 hours and consisted of 5 females and 6 males,. The controls had an average age-at-death of 80.4 ± 10.0 
years and a post-mortem delay of 30.0 ± 16.8 hours and consisted of 3 females and 12 males. The MRC 
identifier numbers for each case are supplied in Supplementary Table 1. 
 
Pure DLB cases were diagnosed according to consensus neuropathological criteria (McKeith et al. 2005). All 
DLB cases had Braak stage 5 or 6 Lewy body pathology (Braak et al. 2003). Cases were excluded on the basis 
of a neuropathological diagnosis of AD based on the National Institute on Aging-Alzheimer’s Association 
guidelines for the neuropathological assessment of AD (Montine et al. 2012)) or the presence of a 
neurodegenerative disease apart from DLB. They were also excluded if there was evidence of severe cerebral 
amyloid angiopathy or any other significant cerebrovascular disease. Controls had no history of dementia and no 
neuropathological abnormalities apart from mild neurofibrillary tangle pathology (Braak tangle stage III or less) 
and scattered diffuse Aβ plaques in some cases. 
 
Brain tissue 
Cortical brain tissue (~200 mg), dissected from the cingulate cortex (Brodmann area 24), was homogenized in 
1% NP-40 buffer (140 mM NaCl, 3 mM KCl, 25 mM Tris pH 7.4, 5 mM EDTA, 2 mM 1,10-phenanthroline, 
0.1 M PMSF, 1.7 mg/ml aprotinin, NP-40 detergent) in a Precellys 24 homogenizer (Stretton Scientific, 
Derbyshire, UK) with 2.3 mm silica beads (Biospec, Glasgow, UK). The homogenates were centrifuged at 
13000 rpm for 15 min at 4°C and the supernatant (soluble extract) removed, aliquoted and stored at −80°C. 
Insoluble pelleted material was solubilized by vigorous agitation in 6 M GuHCl (insoluble extract) and left for 4 
h at room temperature (RT) before storage at −80°C.Total protein concentrations were determined using the 
Total Protein Kit (Sigma Aldrich, Dorset, UK) following the manufacturer’s guidelines. 
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Assessment of cleavage of α-syn in vitro 
 
Recombinant human full-length wild-type α-syn (5 ng) (rPeptide, Stratech, Suffolk, UK) was incubated with 
recombinant human ECE-1 or ECE-2 (50 – 1.56 ng) (R&D systems, Oxford, UK) at 37°C with shaking 
(300rpm) in a non-binding black 96-well plate. The reaction was performed either at a neutral pH (PBS or 
water) or in a mildly acidic assay buffer for ECE-1 (0.1 M MES, 0.1 M NaCl, pH 6.0) and ECE-2 (0.1 M MES, 
0.25 M NaCl, pH 5.5). The reaction was allowed to proceed for 24 hours and samples from the reaction mix 
were removed at various time points (0, 5, 10, 30, 60 minutes and 2, 4, 6 and 24 hours). Reaction samples were 
diluted in sample buffer (0.5 M Tris–HCl, pH 6.8, 0.25% glycerol, 10% (w/v) SDS, 0.5% (w/v) bromophenol 
blue) containing 5% β-mercaptoethanol and denatured by heating at 95°C for 5 min. They were electrophoresed 
on a 4–20% gradient pre-cast Tris–HCl gel (BioRad, Hemel Hempstead, UK) for 1 h at 150 mV alongside the 
Precision Plus protein Western C standards (BioRad). Proteins were subsequently transferred onto nitrocellulose 
membrane (GE Healthcare, UK, Limited) in a Mini Trans-Blot Cell (BioRad) at 90 mV for 1.5 hours on ice. 
Membranes were immersed for 1 h in 10% non-fat dried milk powder in Tris-buffered saline-Tween 20 
(0.05%), washed briefly in TBS-T (15 min, room temperature, with agitation x3) and probed with mouse anti-
human α-syn (syn-1) (1 in 1000) (BD Biosciences, Oxford, UK) diluted in 5% non-fat dried milk/TBS-T 
(1:1000, at 4°C overnight with agitation). The membrane was washed in TBS-T (3 × 15 min, with agitation) and 
incubated with anti-mouse peroxidase-conjugated secondary antibody (Vector labs, Burlingame, CA, U.S.A) 
diluted in 5% non-fat dried milk/TBS-T (1:4000, 2 h, room temperature, with agitation). Membranes were 
washed in TBS-T (3 × 15 min, with agitation) and immune-labelled proteins visualised using the Enhanced 
Chemiluminescence (ECL) Detection System (Amersham Biosciences, Buckinghamshire, UK). ECL detection 
reagents were applied (5 min) and membranes were visualised using the ChemiDoc XRS+ system (Biorad). 
Volumetric analysis of the relative band density was performed using Image Lab 5.0 software. 
 
ECE-1 and ECE-2 sandwich ELISAs 
ECE-1 protein level was measured in NP-40-soluble brain tissue extracts (total protein 10 µg) and SH-SY5Y 
cell lysates (total protein 30 µg) using a commercially available sandwich ELISA kit (catalogue number 
SEA483Hu) (USCN, Wuhan, Hubei Province 430206, P.R. China) and was interpolated from a standard curve 
generated from a serial dilution of recombinant human ECE-1 (2000−31.25 pg/ml). Measurements for each 
sample were made in duplicate. ECE-2 protein level was also measured by a commercially available sandwich 
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ELISA kit (catalogue number CSB-EL007372HU) (Cusabio, Wuhan, Hubei Province 430206, P.R. China). 
ECE-2 concentration in brain tissue extracts (total protein 25µg) and SH-SY5Y cell lysates (total protein 25µg) 
was interpolated from a standard curve produced by serial dilution of recombinant human ECE-2 (3000−46.8 
pg/ml) and measured in duplicate. 
 
α-syn and α-syn-P129 sandwich ELISAs 
α-syn and α-syn-P129 levels were measured by sandwich ELISA in GuHCl-solubilised brain tissue extracts and 
SH-SY5Y cell lysates, as previously described (Miners et al. 2014a, Miners et al. 2014b, Swirski et al. 2014) 
For the α-syn ELISA, a mouse monoclonal anti-α-syn antibody (Syn-1, raised against epitope corresponding to 
aa 91–99 (Perrin et al. 2003) (0.5 µg/ml) (BD Biosciences, Oxford, UK) was used as the capture antibody and a 
biotinylated goat polyclonal anti-α-syn (raised against full-length recombinant human α-syn) (1 µg/ml) (R&D 
systems, Oxford, UK) was used as the detection antibody. Total α-syn concentration in brain tissue extracts 
(diluted 1 in 99 in PBS) and SH-SY5Y cell lysates (total protein 8 µg) was determined following interpolation 
from a standard curve produced from a serial dilution of recombinant human α-syn (62.5−0.97 ng/ml) (rPeptide, 
Stratech, Suffolk, UK).  
 
The α-syn-P129 ELISA was performed as previously described (Miners et al. 2014a, Miners et al. 2014b).  
Briefly, a mouse monoclonal anti-α-syn antibody (syn-1) (0.5 µg/ml) (BD Biosciences, Oxford, UK) was used 
as the capture antibody and biotinylated anti-α-syn-129 (0.8 µg/ml, Abcam, Cambridge, UK) as the detection 
antibody. α-syn-P129 concentration was determined in brain tissue extracts (diluted 1:99 in PBS) and SH-SY5Y 
cell lysates (total protein 8 µg) following interpolation against a standard curve produced from a serial dilution 
of recombinant α-syn (200–3.25 ng/ml) (rPeptide, Stratech, UK) that had been phosphorylated at serine 129 by 
incubation with casein kinase II (New England Biolabs, Hitchin, UK) for 1 h at 30°C in the presence of ATP 
(New England Biolabs, Hitchin, UK) as previously described (Miners et al. 2014a, Swirski et al. 2014). The 
specificity of the ELISA for α-syn-P129 was previously demonstrated (Miners et al. 2014a, Swirski et al. 2014). 
 
SH-SY5Y cell culture and transient siRNA-mediated knockdown of ECE-1 and ECE-2  
SH-SY5Y cells (American Type Culture Collection (ATCC, CRL-2266)) and SH-SY5Y cells transfected with 
full-length human wild-type α-synuclein  (SH-SY5Y-α-syn) were maintained in Ham’s F12 nutrient mixture 
(F12) (42% vol/vol), Eagle’s minimum essential medium (MEM) (42% vol/vol) supplemented with foetal calf 
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serum (15% vol/vol), 2 mM L-glutamine, non-essential amino acids solution (1% vol/vol), penicillin (20 
units/ml)/streptomycin (20 mg/ml) and amphotericin B (250 ng/mL), at 37°C in 5% CO2/21% O2. All tissue 
culture reagents were purchased from Sigma Aldrich (Sigma Aldrich, Dorset, UK). 
SH-SY5Y cells were transiently transfected with siRNA directed against ECE-1 or ECE-2 using the 
Amaxa Cell Line Nucleofactor Kit V (Lonza, Basel, Switzerland) using program G-004 on a Nucleofactor 
device (Lonza, Basel, Switzerland). In brief, cells were cultured for 3-4 days until ~80% confluent and 
electroporation was performed on ~1.8 x 10
6 
cells, which were nucleofected with siRNA targeted against ECE-1 
(100 nM) or ECE-2 (30 nM) (Life Technologies, Warrington, UK) and seeded overnight in a 6-well plate. The 
conditioned medium was removed, centrifuged at 13,000 rpm for 10 minutes to remove any cellular debris, and 
stored at -80°C until used. The cells were subsequently washed in PBS, detached in PBS without magnesium 
and chloride (Sigma Aldrich, Dorset, UK), pelleted and lysed in non-denaturing Cell Lytic 
TM 
cell lysis buffer 
(Sigma Aldrich, Dorset, UK). The samples were centrifuged at 13,000 rpm for 15 min at 4°C and the 
supernatants aliquoted and stored at -80°C until used. Total protein level was determined using Total Protein Kit 
(Sigma Aldrich, Dorset, UK) and volumes were adjusted to add an equal amount of total protein per sample for 
measurement of ECE-1, ECE-2, and α-syn by sandwich ELISA, as described above. Each experiment was 
repeated in duplicate and performed on at least three separate occasions. 
 
Double immunofluorescent labelling of ECE-1/ECE-2 and α-syn 
SH-SY5Y and  SH-SY5Y-α-syn cells were grown on poly-L-lysine (PLL)-coated coverslips, washed in PBS x3, 
fixed in 4% paraformaldehyde for 10 min, further washed in PBS and blocked for 30 min in PBS with 0.5% 
triton-X100 and 5% horse serum (Millipore, Nottingham, UK). Immunofluorescent labelling was firstly 
optimised for α-syn using mouse monoclonal α-syn (syn-1) (2.5 µg/ml) (BD, Oxford, UK) as previously 
described (Miners et al. 2014a). ECE-1 (goat polyclonal anti-ECE-1, R&D systems, Cambridge, UK) and ECE-
2 (goat polyclonal ECE-2, R&D systems, Cambridge, UK) immunofluorescence was optimised and a panel of 
established endolysosomal markers (New England Biolabs, Herts, UK) was used according to the 
manufacturer's guidelines. For double-immunofluorescence we added antibody pairs for 1 h at RT, followed by 
Alexa-fluor-488 and -555 (Invitrogen, Life Technologies, Paisley, UK) at 1:1000 for 1 h at RT in the dark. 
Images were acquired under an x100 objective with a confocal scanning laser microscope. 
 
Proximity ligation assay 
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An in-situ proximity ligation assay was performed using a Duolink kit as per manufacturer’s guidelines (Sigma 
Aldrich, Dorset, UK). In brief, SH-SY5Y cells were grown on PLL-coated coverslips and fixed in 
paraformaldehyde as above.  Mouse monoclonal α-syn (2.5 µg/ml, BD, Oxford, UK) was used with either goat 
polyclonal ECE-1 (R&D systems, Cambridge, UK) or goat polyclonal ECE-2 (R&D systems, Cambridge, UK). 
For negative controls one of the antibodies for each pair was omitted. The experiments were repeated in 
triplicate. 
 
Statistical analysis 
Parametric statistical tests were used where possible for group comparisons (this required logarithmic 
transformation of the data for some cases to obtain a normal distribution). ANOVA with a Bonferroni post-hoc 
test was used for multiple-group comparisons. For datasets that were not normally distributed even after 
transformation, a Kruskall-Wallis test with Dunn’s test for pairwise intergroup comparisons was used. Pearson 
analysis was used to assess the correlation between pairs of variables. Statistical tests were performed with the 
help of SPSS version 23. P-values < 0.05 were considered statistically significant. 
 
Results 
ECE-1 and ECE-2 cleave α-syn in vitro 
Recombinant human ECE-1 and ECE-2 cleaved full-length recombinant human α-syn resulting in a reduction of 
monomeric α-syn (~16kda band) in a time- (Figure 1) and dose-dependent (Figure 2) manner. ECE-1 and ECE-
2 mediated α-syn cleavage resulted in a greater than 50% reduction in the density of monomeric α-syn at 5 
minutes with almost complete cleavage observed at ~ 2hrs (Figure 1). ECE-1 and ECE-2 (50ng – 1.56ng) 
cleaved human α-syn in a dose-dependent manner (Figure 2). ECE-1 and ECE-2 cleaved α-syn at a mildly 
acidic pH resulting in a similar time-dependent reduction of monomeric α-syn observed at a neutral pH (Figure 
3). In comparison to ECE-1, recombinant human α-syn was not cleaved by recombinant human neprilysin 
(NEP), human angiotensin-converting enzyme-1 (ACE-1), or human insulin-degrading enzyme (IDE) 
(Supplementary Figure 1). ECE-mediated cleavage of recombinant human α-syn was inhibited in the presence 
of phosphoramidon (100µM) (Supplementary Figure 2).  
 
 
ECE-1 and ECE-2 regulate intracellular and extracellular α-syn level in vitro 
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To assess the possible functional significance of ECE in the homeostasis of α-syn, we measured the level of α-
syn in SH-SY5Y cells following transient siRNA-mediated knock-down of ECE-1 or ECE-2. A modest 
reduction in the expression of ECE-1 (~25% reduction in ECE-1 protein level as measured by ELISA) resulted 
in significantly increased endogenous α-syn level, both in the cell lysate (~50% increase in α-syn level as 
measured by ELISA) and in the surrounding culture medium (~40% increase in α-syn level as measured by 
ELISA) (Figure 4A-C). siRNA-mediated transient knockdown of ECE-2 caused a ~60% reduction in ECE-2 
protein level as measured by ELISA, and produced a significant increase in α-syn in the cell lysate (~30% 
increase in α-syn level as measured by ELISA). A non-significant increase in α-syn level was also measured in 
the surrounding medium (~20% increase in α-syn level as measured by ELISA) (Figure 4D-F). 
 
 
ECE-1 and ECE-2 interact with α-syn within the endolysosomal pathway 
Co-localisation of ECE-1 with α-syn was observed in SH-SY5Y cells and SH-SY5Y cells overexpressing 
human α-syn (SH-SY5Y-α-syn) (Figure 5). α-syn was endogenously expressed throughout the cytoplasm in SH-
SY5Y cells (Figure 5A) and was increased in SH-SY5Y-α-syn cells (Figure 5D). ECE-1 was abundantly 
expressed throughout the cytoplasm (Figure 5B and E) where it co-localised with markers of maturing 
endosomes (mannose-6-phosphate receptor and Rab 7) (Supplementary Figure 3). ECE-1 also co-localised with 
α-syn (Figure 5C and F) and the amount of co-localisation between ECE-1 and α-syn appeared visually greater 
within individual cells in SH-SY5Y-α-syn cells (Figure 5F). ECE-2 was also distributed throughout the 
cytoplasm but had a more punctate appearance (Figure 6B and E) (a small degree of co-localisation was 
observed between ECE-2 and markers of early endosomes - early endosome autoantigen 1 (EEA1) and Rab 5 
(Supplementary Figure 4)). Merged images show focal points of co-localisation between ECE-2 and α-syn in 
SHSY-5Y (Figure 6C) and SH-SY5Y-α-syn cells (Figure 6F). To confirm that ECE-1 and ECE-2 were localised 
within close proximity of α-syn, we used a proximity ligation assay (Figure 7). These images demonstrate co-
localisation of both ECEs with α-syn, at a distance of 15nM or less. As with double immunofluorescence studies 
co-localisation of α-syn with ECE-1 was more apparent than with ECE-2.  
 
ECE-1 and ECE-2 level is reduced in DLB and correlates inversely with α-syn-P129 
To determine whether the levels of ECEs are altered in Lewy body disease and potentially contribute to the 
pathogenesis of DLB we measured ECE-1, ECE-2, α-syn and α-syn-P129 levels in cingulate cortex from DLB 
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and control brains by ELISA. We showed previously that α-syn-P129 is a reliable indicator of severity of Lewy 
body pathology (Miners et al. 2014a, Swirski et al. 2014). ECE-1 and ECE-2 levels were significantly reduced 
in DLB compared to age-matched controls (Figure 8A-B). Reduced ECE-1 and ECE-2 levels correlated 
inversely with increasing α-syn-P129 level across the cohorts (Figure 8C-D).  
 
Discussion 
Endothelin-converting enzymes are expressed throughout the brain and are involved in the hydrolysis of a range 
of biologically diverse peptides. Alterations in ECE activity have been suggested to be involved in the 
pathogenesis of Alzheimer’s disease, as ECEs were shown to cleave amyloid-β (Aβ) (Eckman et al. 2001), the 
levels of which are elevated in ECE-knockout mice (Eckman et al. 2003). Here we have shown for the first time 
that ECEs cleave α-syn and that knockdown of either ECE-1 or ECE-2 increases the amount of both 
intracellular and extracellular α-syn. We have also shown that ECEs interact with α-syn within the 
endolysosomal pathway in SH-SY5Y cells. We have shown too that ECE-1 and ECE-2 levels are significantly 
reduced in cingulate cortex (an area with a predilection for α-syn accumulation in Lewy bodies in DLB (Miners 
et al. 2014a, Swirski et al. 2014)) in post-mortem brain tissue from people with DLB, and that the concentration 
of α-syn-P129 (which accounts for ~90% of the α-syn within Lewy bodies (Anderson et al. 2006, Fujiwara et al. 
2002)) correlated with the extent of reduction in ECEs in the same tissue samples. Together these findings 
suggest a novel role for ECEs in the homeostasis of α-syn and suggest that deficient enzyme activity may 
contribute to the pathogenesis of DLB, although further work is required. 
ECEs are expressed throughout the brain. ECE-1 is expressed abundantly in endothelial cells but has 
also been identified within non-vascular cells within the CNS such as pyramidal neurons, cerebellar Purkinje 
cells and astrocytes (Naidoo et al. 2004, Palmer et al. 2010). Of the four isoforms, ECE-1a and ECE-1c are 
mainly expressed at the plasma membrane whereas ECE-1d and ECE-1b are localised to intracellular 
compartments including the recycling and late endosomes (Azarani et al. 1998, Muller et al. 2003, Schweizer et 
al. 1997). ECE-2 is expressed predominantly by pyramidal neurons in the CNS (Palmer et al. 2009) and has four 
isoforms that are expressed intracellularly. ECE-1 and ECE-2 degrades a variety of neuropeptides within 
endosomes and are responsible for regulating receptor recycling during neuropeptide signalling (Padilla et al. 
2007, Roosterman et al. 2007, Roosterman et al. 2008, Gupta et al. 2015).  
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It is becoming increasingly clear that disturbances in clearance play a major role in the accumulation of 
a range of aggregation-prone, disease-related proteins within the brain. Many of the pathways involved in the 
clearance of α-syn are dysregulated in Lewy body diseases (reviewed in (Deleidi & Maetzler 2012, Ebrahimi-
Fakhari et al. 2012, Webb et al. 2003, Xilouri et al. 2013)). There is strong evidence that dysregulation of the 
ubiquitin-proteosomal pathway and the autophagy-lysosomal system (cathepsin D is an important mediator of 
degradation of α-syn within the lysosome) (Cullen et al. 2009, Qiao et al. 2008, Sevlever et al. 2008)) are 
involved in the accumulation of α-syn in Lewy body diseases. Another probable contributor to this accumulation 
is a reduction in CAPN1 and KLK6, two recently identified α-syn-degrading proteases, the levels of which we 
recently reported to be reduced within the cingulate cortex in DLB and were inversely correlated with the level 
of α-syn phosphorylated at Ser129 (Miners et al. 2014a), as was the case for the concentration of ECEs in the 
present study.  
Discrete intracellular pools of α-syn have been detected in early, late and recycling endosomes 
(Hasegawa et al. 2011, Lee et al. 2008), multi-vesicular bodies and lysosomes (Boassa et al. 2013), autophagic 
vesicles following chaperone-mediated autophagy (Mak et al. 2010), and exosomes (Lee et al. 2005). 
Dysregulation of the endo-lysosomal and autophagic systems, which occurs early in the development of Lewy 
body diseases, has been implicated in the accumulation, vesicular spread and trans-neuronal propagation of 
pathogenic α-syn (Luk et al. 2012, Mougenot et al. 2011, Mougenot et al. 2012, Masuda-Suzukake et al. 2013). 
Our data show that ECEs interact with α-syn within several intracellular locations that impact on the secretion of 
α-syn, although further work is required to confirm this. Our findings are similar to the observations of Pacheco-
Quinto et al., 2013 (Pacheco-Quinto & Eckman 2013) who demonstrated that ECEs degrade discrete pools of 
vesicular Aβ: ECE-2 cleaved an intracellular pool of Aβ which was produced and degraded within the 
autophagic and endo-lysosomal pathway whereas ECE-1 (although contributing to both pathways) 
predominantly degraded a pool of Aβ destined for secretion. A recent study demonstrated that an increase in 
KLK6, which is synthesised as an inactive zymogen and secreted extracellularly whereupon it is activated and 
degrades extracellular α-syn (Tatebe et al. 2010), could also reduce the transcellular spread of pathogenic α-syn 
(Yamashiro et al. 1997). Further work is required to determine whether ECEs, particularly ECE-1 might 
influence the transcellular spread and CNS accumulation of α-syn as postulated for KLK6.  
In this study, we have shown that ECE-1 and ECE-2 degrade full-length monomeric α-syn at both a 
neutral and mildly acidic pH in a time- and dose-dependent manner. Over 50% reduction of monomeric α-syn 
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was observed in the first five minutes with complete degradation observed at 2 hours. This is in-keeping with 
relatively rapid CTSD (Sevlever et al. 2008) and CAPN-1 mediated degradation of α-syn (Dufty et al. 2007) in 
contrast to slower and incomplete KLK6-mediated cleavage (6-24 hours) (Kasai et al. 2008). To fully 
understand the potential role of ECE-1 and -2 in the pathogenesis of Lewy body diseases, such as DLB, 
however, requires further mapping of ECE-mediated α-syn cleavage sites and characterisation of the cleavage 
fragments within human brain tissue and in animal studies. It has been established that cleavage within the NAC 
domain reduces the aggregation of full-length wild-type α-syn, as shown for KLK6 (Kasai et al. 2008). C-
terminal truncation on the other hand, as shown for CAPN1 (Dufty et al. 2007, Mishizen-Eberz et al. 2005), and 
MMP-3 (Choi et al. 2011, Sung et al. 2005) mediated cleavage of fibrillary α-syn produces fragments that 
accelerate the aggregation of α-syn. CAPN1-mediated cleavage of α-syn has been postulated to accelerate 
disease (Higuchi et al. 2012, Yamashima 2013) whereas KLK6-mediated cleavage (Spencer et al. 2013) and 
CTSD cleavage (Cullen et al. 2009, Qiao et al. 2008) is protective. It also remains to be determined whether 
disease-associated mutant forms of α-syn (such as those carrying A53T or A30P mutations), or phosphorylated 
forms of α-syn, are resistant to ECE-mediated degradation as previously shown for KLK6 and CAPN1 (Iwata et 
al. 2003, Kasai et al. 2008, Mishizen-Eberz et al. 2003). Lastly, the ability of ECE to cleave such a relatively 
large substrate (Mr of α-syn is 14kDa) compared to most neuropeptides and beta amyloid (between 1-4 KDa) is 
also unusual and is not shared by closely related metallo-endopeptidases such as neprilysin and insulin-
degrading enzyme.  
In conclusion, we present novel evidence that ECEs cleave and degrade α-syn in vitro and may 
contribute to the homeostasis of α-syn and the pathogenesis of Lewy body diseases. 
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Figure Legends 
 
Figure 1. Time course of ECE-1 and ECE-2 cleavage of α-syn in vitro. Full-length wild-type recombinant 
human α-syn (5ng) was incubated with recombinant human ECE-1 and ECE-2 (50ng) in either distilled water or 
PBS and incubated at 37°C with shaking for 18 hours. Samples were taken at various time-points and 
transferred to a nitrocellulose membrane followed by western blotting with mouse monoclonal anti-α-syn (syn-
1). A-B representative western blots of ECE-2 mediated α-syn cleavage performed in distilled water and PBS 
from a single experiment. C-D Bar charts showing the relative band density of monomeric α-syn (~16 kDa), at 
the different time-points (expressed as a percentage of the control at 0 minutes which was arbitrarily assigned a 
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value of 100%) up to 2 hours following incubation with ECE-1 and ECE-2. No bands were detected at 4, 6 and 
18 hours (not shown). Each experiment was repeated in duplicate and the bars represent the mean ± standard 
deviation. 
 
Figure 2. Dose-dependent cleavage of α-syn by ECE-1 and ECE-2 in vitro.  Full-length recombinant α-syn, 
diluted in distilled water, was incubated with recombinant human ECE-1 and ECE-2 at various concentrations 
(50 – 1.25ng) in distilled water for 10 minutes before samples were transferred to a nitrocellulose membrane 
followed by western blotting with mouse monoclonal anti-α-syn (syn-1). A representative image showing dose-
dependent ECE-1 mediated reduction in monomeric α-syn (~16 kDa) from a single experiment. B Bar chart 
showing the relative band density of monomeric α-syn (~16 kDa) following incubation at the different 
concentrations of ECE-1 and ECE-2 (expressed as a percentage of the control at 0 minutes which was arbitrarily 
assigned a value of 100%). Each experiment was repeated in duplicate and the bars represent the mean ± 
standard deviation. 
 
Figure 3. ECE-1 and ECE-2 cleavage of α-syn at mildy acidic pH in vitro. Full-length α-syn was incubated 
with recombinant human ECE-1 (50ng, pH 6.0) and ECE-2 (50ng, pH 5.5) at a mildly acidic pH. A-B 
representative images showing the time course of monomeric α-syn cleavage by ECE-1 and ECE-2 at pH 6.0 
and pH 5.5 respectively from a single experiment. C Bar chart showing the relative band density of monomeric 
α-syn at the different time-points (expressed as a percentage of the control at 0 minutes which was arbitrarily 
assigned a value of 100%) up to 2 hours. Each experiment was repeated in duplicate and the bars represent the 
mean ± standard deviation. No bands were detected at 4, 6 and 18 hours (not shown). 
 
Figure 4. ECE-1 and ECE-2 regulate an intracellular and extracellular pool of α-syn in SH-SY5Y cells. A-
C siRNA-mediated knockdown of ECE-1 (~25% reduction) resulted in increased α-syn levels in the cell lysate 
(~50%) and in the cell medium (~40%) of SH-SY5Y cells. D-F siRNA-mediated knockdown of ECE-2 (~60% 
reduction) resulted in increased α-syn levels in the cell lysate (~30%) and, although not significant, increased α-
syn level within the cell medium (~20%). ECE-1, ECE-2 and α-syn level were measured by sandwich ELISA in 
cell lysates adjusted for total protein. Experiments were repeated on at least three separate occasions. P < 0.05 
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Figure 5. ECE-1 co-localised with α-syn in SH-SY5Y neuroblastoma cells overexpressing human wild-
type α-syn (SH-SY5Y-α-syn). A and D show widespread cytoplasmic distribution of α-syn (green) in SH-
SY5Y cells which was increased in SH-SY5Y cells stably transfected to overexpress human α-syn (SH-SY5Y-
α-syn). B and E ECE-1 (red) was abundant and had a distinctive perinuclear distribution in both cell lines. C 
and F In merged images, ECE-1 co-localised (orange-yellow) with α-syn which appeared visually greater within 
individual cells in SH-SY5Y-α-syn cells. Images were acquired under a x60 objective with a confocal scanning 
laser microscope. Nuclei were stained with DAPI (blue). Representative images are from a single experiment. 
Each experiment was performed independently on at least two separate occasions. 
 
Figure 6. ECE-2 co-localised with α-syn in SH-SY5Y neuroblastoma cells overexpressing human wild-
type α-syn (SH-SY5Y-α-syn). A and D α-syn (green) showed widespread cytoplasmic distribution in SH-
SY5Y cells which was increased in SH-SY5Y cells stably transfected to overexpress human α-syn (SH-SY5Y-
α-syn). B and E ECE-2 (red) had a punctate appearance in both wild-type SH-SY5Y cells and SH-SY5Y-α-syn 
cells. C and F Double immunofluorescence revealed foci of co-localisation (orange-yellow) of ECE-2 and α-
syn. Images were acquired under a x60 objective with a confocal scanning laser microscope. Nuclei were 
stained with DAPI (blue). Representative images are from a single experiment. Each experiment was performed 
independently on at least two separate occasions. 
 
 
Figure 7. Co-localisation of ECE-1 and ECE-2 with α-syn was confirmed using a proximity ligation assay 
in SH-SY5Y cells. A Co-localisation of ECE-1 and α-syn was confirmed in SH-SY5Y cells (red dots). B 
Negative control had omission of ECE-1. C Co-localisation of ECE-2 and α-syn was confirmed in the same cell 
line. D. Negative control had omission of ECE-2 antibody. Images were acquired under a x60 objective with a 
confocal scanning laser microscope. Nuclei were stained blue with DAPI. Representative images are from a 
single experiment. Each experiment was performed independently on at least two separate occasions. 
 
 
Figure 8. ECE-1 and ECE-2 levels were reduced in human post mortem brain tissue the cingulate cortex 
in dementia with Lewy bodies (DLB). A-B Reduced ECE-1 and ECE-2 (measured by sandwich ELISA) in the 
cingulate cortex, a region with a predilection to Lewy body pathology, in DLB. C-D Scatterplots showing ECE-
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1 and ECE-2 level correlated inversely with the level of α-syn phosphorylated at Ser129 (a marker of Lewy 
body pathology) measured by sandwich ELISA in the same samples. * P < 0.05;** P < 0.01; *** P < 0.001 
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Table 1. Study cohort  
 DLB (n = 11)  Control (n = 15) 
Age (y ± SD) 77.7 ± 8.9  80.4 ± 10.0 
Gender (F:M) 5:6 3:12 
PM delay (h ± SD) 28.2 ± 10.3 30.0 ± 16.8 
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Miners JS et al., Endothelin-converting enzymes degrade α-synuclein and are reduced in dementia with 
Lewy bodies  
 
Supplementary Figure 1. Comparison of α-synuclein cleavage in vitro by endothelin-converting enzyme-1 
(ECE-1), neprilysin (NEP), angiotensin-converting enzyme-1 (ACE-1) and insulin-degrading enzyme (IDE). 
Full-length wild-type recombinant human α-syn (5ng) was incubated, either alone (-), or with recombinant 
human ECE-1, NEP, ACE-1, and IDE (all at 50ng) in distilled water at 37°C with shaking for 2 hours. Samples 
were transferred to a nitrocellulose membrane followed by western blotting with mouse monoclonal anti-α-syn 
(syn-1). Representative western blot showing full-length monomeric α-syn (~16 kDa). This is a representative 
image from a single experiment. The experiment was performed independently on two separate occasions. 
 
 
Page 32 of 37Journal of Neurochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Supplementary Figure 2.  ECE-2 mediated cleavage of α-synuclein (α-syn) is inhibited in the presence of 
phosphoramidon (PA). Full-length wild-type recombinant human α-syn (5ng) was incubated, either alone, or 
with recombinant human ECE-2 (100ng), with and without phosphoramidon (PA) (100µM), in distilled water at 
37°C with shaking for 2 hours. Samples were transferred to a nitrocellulose membrane followed by western 
blotting with mouse monoclonal anti-α-syn (syn-1). Representative western blot showing full-length monomeric 
α-syn (~16 kDa). This is a representative image from a single experiment. The experiment was performed 
independently on two separate occasions. 
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Supplementary Figure 3. ECE-1 co-localised with markers of the ‘late/maturing’ endo-lysosomal system in 
SH-SY5Y cells. In merged images ECE-1 (red) co-localised (orange-yellow) with (A) mannose-6 phosphate 
receptor (M6PR) (green) and (B) Rab7 (green), markers of late and maturing endosomes respectively. Images 
were acquired under a x100 objective with a confocal scanning laser microscope. 
 
 
 
 
Supplementary Figure 4. ECE-2 co-localised with markers of the ‘early’ endo-lysosomal system in SH-SY5Y 
cells. A low level of co-localisation (orange-yellow) was observed between ECE-2 (red) and (A) early 
endosome antigen 1 (EEA1) (green) and B. Rab5 (green), markers of early endocytosis. Images were acquired 
under a x100 objective with a confocal scanning laser microscope. 
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Diagnosis  Age-at-
death (y)  
Gender  Post-
mortem 
delay  
MRC 
identifier  
DLB  68  M  24  BBN_9017  
DLB  75  M  53  BBN_9039  
DLB  77  M  21  BBN_9064  
DLB  97  F  24  BBN_9135  
DLB  76  F  33  BBN_9316  
DLB  86  M  15.25  BBN_9321  
DLB  69  M  38  BBN_9334  
DLB  85  F  30  BBN_4198  
DLB  79  F  26  BBN_9351  
DLB  76  M  26  BBN_9370  
DLB  67  F  20  BBN_9384  
Control  64  M  12  BBN_8700  
Control  75  M  48  BBN_8759  
Control  69  M  66  BBN_8779  
Control  82  M  3  BBN_8923  
Control  72  F  24  BBN_8980  
Control  76  M  23  BBN_9028  
Control  73  M  35  BBN_9292  
Control  90  M  5.5  BBN_9299  
Control  93  M  37.75  BBN_9311  
Control  94  F  21  BBN_9340  
Control  92  M  34.25  BBN_9344  
Control  87  M  24  BBN_4205  
Control  85  M  30.5  BBN_9354  
Control  87  M  47  BBN_4229  
Control  68  F  38.75  BBN_9389  
 
Supplementary Table 1. MRC identifiers 
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In this issue. Defective clearance, rather than increased production, most likely contributes to intracellular 
accumulation of α-synuclein in Lewy body diseases, including dementia with Lewy bodies (DLB) and 
Parkinson’s disease (PD). Several enzymes are capable of degrading α-synuclein (as shown) and are often 
dysregulated in DLB and PD. Here we show for the first time that recombinant human α-synuclein is cleaved by 
endothelin-converting enzyme-1 and -2 (ECE-1/-2) and siRNA-mediated knockdown of ECE-1 or -2 increased 
intracellular and extracellular α-syn within SH-SY5Y cells. ECE-1 and -2 co-localise with discrete pools of 
intracellular α-synuclein that are implicated in the spread and propagation of Lewy body pathology. Finally, we 
show that ECE-1 and -2 levels are significantly reduced in post-mortem brain tissue in the cingulate cortex in 
DLB and correlate inversely with Lewy body pathology.  
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